Biogen Inc. (BIIB) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Core Insights - Biogen has been undergoing significant changes over the past 2.5 years, facing challenges in its multiple sclerosis (MS) portfolio and slower-than-expected growth from its new drug LEQEMBI [3] Company Overview - The company has recognized that success in the biopharma industry often leads to challenges, particularly due to the instability associated with patent life [3] - Biogen's MS portfolio, which includes several strong drugs, has been experiencing a gradual decline [3] Strategic Decisions - A major strategic decision was made to withdraw all promotional activities from the MS portfolio, which surprisingly did not negatively impact sales trajectories [4]